Artificial Glycoproteins as a Scaffold for Targeted Drug Therapy.

Akin to a cellular "fingerprint," the glycocalyx is a glycan-enriched cellular coating that plays a crucial role in mediating cell-to-cell interactions. To gain a better understanding of the factors that govern in vivo recognition, artificial glycoproteins were initially created to probe changes made to the accumulation and biodistribution of specific glycan assemblies through biomimicry. As a result, the organ-specific accumulation for a variety of glycoproteins decorated with simple and/or complex glycans was identified. Additionally, binding trends with regard to cancer cell selectivity were also investigated. To exploit the knowledge gained from these studies, numerous groups thus became engaged in developing targeted drug methodologies based on the use of artificial glycoproteins. This has either been done through adopting the glycoprotein scaffold as a drug carrier, or to directly glycosylate therapeutic proteins/enzymes to localize their biological activity. The principle aim of this Review is to present the foundational research that has driven artificial glycoprotein-based targeting and subsequent adaptations with potential therapeutic applications. © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Citation

Kenward Vong, Tomoya Yamamoto, Katsunori Tanaka. Artificial Glycoproteins as a Scaffold for Targeted Drug Therapy. Small (Weinheim an der Bergstrasse, Germany). 2020 Jul;16(27):e1906890

Mesh Tags

Substances

PMID: 32068952

search → result